Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
We can see a decrease in the price for Akebia Therapeutics Inc.. Compared to yesterday it has lost -€0.015 (-1.480%).
With 8 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 3 € there is potential for a 194.41% increase which would mean more than doubling the current price of 1.02 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Akebia Therapeutics Inc. | -1.480% | -3.890% | -20.921% | -20.983% | -13.567% | -64.580% | - |
Ardelyx Inc. | -10.570% | -3.853% | 15.454% | 108.097% | 19.170% | 20.842% | - |
Evolus Inc | -5.830% | 2.564% | 13.208% | 34.078% | 32.597% | 61.074% | - |
Salarius Pharmaceuticals Inc. | 5.580% | 3.141% | -10.860% | -67.167% | -29.009% | -98.470% | -99.993% |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The